{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:15:58Z","timestamp":1790691358164,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T00:00:00Z","timestamp":1508716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.clgc.2017.10.010","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T15:32:16Z","timestamp":1508859136000},"page":"e469-e476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2222-3531","authenticated-orcid":false,"given":"Joseph W.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Sun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youna","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insoo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Petrylak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2017.10.010_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2017.10.010_bib2","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2017.10.010_bib3","doi-asserted-by":"crossref","first-page":"e28643","DOI":"10.4161\/onci.28643","article-title":"Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens","volume":"3","author":"Gameiro","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clgc.2017.10.010_bib4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1667\/RR13374.1","article-title":"Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy","volume":"182","author":"Wattenberg","year":"2014","journal-title":"Radiat Res"},{"key":"10.1016\/j.clgc.2017.10.010_bib5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fonc.2012.00104","article-title":"In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer","volume":"2","author":"Kwilas","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2017.10.010_bib6","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1158\/0008-5472.CAN-04-1525","article-title":"Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes","volume":"64","author":"Garnett","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2017.10.010_bib7","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1158\/1078-0432.CCR-08-0335","article-title":"The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing","volume":"14","author":"Chakraborty","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2017.10.010_bib8","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clgc.2017.10.010_bib9","doi-asserted-by":"crossref","first-page":"69014","DOI":"10.18632\/oncotarget.10883","article-title":"Samarium-153-EDTMP (Quadramet(R)) with or without vaccine in metastatic castration-resistant prostate cancer: a randomized Phase 2 trial","volume":"7","author":"Heery","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2017.10.010_bib10","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2017.10.010_bib11","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1158\/1078-0432.CCR-07-5162","article-title":"Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant","volume":"14","author":"Lechleider","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2017.10.010_bib12","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1158\/1078-0432.CCR-04-2062","article-title":"Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer","volume":"11","author":"Gulley","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2017.10.010_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12967-015-0397-0","article-title":"NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy","volume":"13","author":"van den Heuvel","year":"2015","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.clgc.2017.10.010_bib14","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clgc.2017.10.010_bib15","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","article-title":"Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys","volume":"181","author":"Crispin","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clgc.2017.10.010_bib16","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.24499","article-title":"Th17 and natural Treg cell population dynamics in systemic lupus erythematosus","volume":"60","author":"Yang","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clgc.2017.10.010_bib17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1615\/CritRevImmunol.v28.i4.40","article-title":"IL-7 and IL-15: biology and roles in T-Cell immunity in health and disease","volume":"28","author":"Kim","year":"2008","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.clgc.2017.10.010_bib18","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood-2005-09-3560","article-title":"Altered IL-7R{alpha} expression with aging and the potential implications of IL-7 therapy on CD8+ T-cell immune responses","volume":"107","author":"Kim","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2017.10.010_bib19","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1158\/0008-5472.CAN-15-0584","article-title":"Tumor-specific effector CD8+ T cells that can establish immunological memory in humans after adoptive transfer are marked by expression of IL7 Receptor and c-myc","volume":"75","author":"Chandran","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2017.10.010_bib20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ijc.26366","article-title":"IL-13 regulates cancer invasion and metastasis through IL-13Ralpha2 via ERK\/AP-1 pathway in mouse model of human ovarian cancer","volume":"131","author":"Fujisawa","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clgc.2017.10.010_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cyto.2015.05.026","article-title":"Targeting of IL-4 and IL-13 receptors for cancer therapy","volume":"75","author":"Suzuki","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.clgc.2017.10.010_bib22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clgc.2017.10.010_bib23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"10.1016\/j.clgc.2017.10.010_bib24","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol"},{"key":"10.1016\/j.clgc.2017.10.010_bib25","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2017.10.010_bib26","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clgc.2017.10.010_bib27","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2017.10.010_bib28","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clgc.2017.10.010_bib29","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3389\/fimmu.2016.00610","article-title":"Chemoradiation increases PD-L1 expression in certain melanoma and glioblastoma cells","volume":"7","author":"Derer","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.clgc.2017.10.010_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2015.09.019","article-title":"Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer","volume":"52","author":"Lim","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2017.10.010_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2017.10.010_bib32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2016.06.015","article-title":"PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis","volume":"65","author":"Hecht","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2017.10.010_bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.18632\/oncotarget.1719","article-title":"Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing","volume":"5","author":"Gameiro","year":"2014","journal-title":"Oncotarget"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767317303166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767317303166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:28:44Z","timestamp":1761564524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767317303166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1558767317303166"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2017.10.010","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2017.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}